Literature DB >> 21847577

Clinical and histopathological features and immunoreactivity of human choroidal and ciliary melanomas as prognostic factors for metastasis and death.

Camila C Simões1, Mindy K Call, Zélia M Corrêa, Abbot G Spaulding, James J Augsburger.   

Abstract

PURPOSES: To determine the relationship between immunohistochemical reactivity to osteopontin, vimentin, keratin 8/18, LZTS1, and beta-catenin and clinical and histopathological prognostic factors for metastasis and death in archival specimens of primary uveal melanomas, and the prognostic value of the evaluated study variables for death from metastasis.
METHODS: Retrospective analysis of clinical records and formalin-fixed, paraffin-embedded slides of primary uveal melanomas treated by enucleation during May 1 1999, through June 30 2009. Immunofluorescent staining of each tumor was assessed on newly prepared histologic slides after the application of antibodies directed against five biomarkers associated with unfavorable prognosis in uveal melanoma.
RESULTS: After exclusions, our study group consisted of 82 cases. Immunofluorescence was observed in 40.2% of specimens evaluated for keratin, 50.0% evaluated for osteopontin, 26.8% evaluated for β-catenin, 65.9% evaluated for vimentin, and 70.7% evaluated for LZTS1. Through available follow-up, 27 patients (32.9%) were dead of confirmed or suspected metastatic uveal melanoma. None of the patients whose tumor exhibited strong immunoreactivity to β-catenin died of metastasis. In contrast, patients whose tumor exhibited immunoreactivity of any intensity to LZTS1 were more likely to develop metastasis. In multivariate Cox proportional hazards modeling, a composite variable that took into account the immunostaining for both β-catenin and LZTS1 had a statistically significant relationship with patient's survival time.
CONCLUSIONS: Our study suggests that conventional clinical and histopathological prognostic factors, and immunoexpression of β-catenin and LZTS1 combined may allow better prognostication of metastasis than clinical and histomorphological factors alone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847577     DOI: 10.1007/s00417-011-1769-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  42 in total

1.  Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis.

Authors:  K Sisley; I G Rennie; M A Parsons; R Jacques; D W Hammond; S M Bell; A M Potter; R C Rees
Journal:  Genes Chromosomes Cancer       Date:  1997-05       Impact factor: 5.006

2.  Fez1/lzts1 alterations in gastric carcinoma.

Authors:  A Vecchione; H Ishii; Y H Shiao; F Trapasso; M Rugge; J F Tamburrino; Y Murakumo; H Alder; C M Croce; R Baffa
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

3.  The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors.

Authors:  H Ishii; R Baffa; S I Numata; Y Murakumo; S Rattan; H Inoue; M Mori; V Fidanza; H Alder; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

4.  Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size.

Authors:  I W McLean; K S Keefe; M N Burnier
Journal:  Ophthalmology       Date:  1997-05       Impact factor: 12.079

5.  Comparison of survival among eligible patients not enrolled versus enrolled in the Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma.

Authors:  Marta M Gilson; Marie Diener-West; Barbara S Hawkins
Journal:  Ophthalmic Epidemiol       Date:  2007 Jul-Aug       Impact factor: 1.648

6.  Very long-term prognosis of patients with malignant uveal melanoma.

Authors:  Emma Kujala; Teemu Mäkitie; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

7.  An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma.

Authors:  U Fuchs; T Kivelä; P Summanen; I Immonen; A Tarkkanen
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

8.  Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome.

Authors:  Eric Kielhorn; Elayne Provost; Drew Olsen; Thomas G D'Aquila; Bradley L Smith; Robert L Camp; David L Rimm
Journal:  Int J Cancer       Date:  2003-02-20       Impact factor: 7.396

9.  Malignant melanomas contain only the vimentin type of intermediate filaments.

Authors:  J Caselitz; M Jänner; E Breitbart; K Weber; M Osborn
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

10.  Molecular determinants of human uveal melanoma invasion and metastasis.

Authors:  Elisabeth A Seftor; Paul S Meltzer; Dawn A Kirschmann; Jacob Pe'er; Andrew J Maniotis; Jeffrey M Trent; Robert Folberg; Mary J C Hendrix
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

View more
  1 in total

Review 1.  Proteomics of uveal melanoma: a minireview.

Authors:  Søren K O Abildgaard; Henrik Vorum
Journal:  J Oncol       Date:  2013-09-03       Impact factor: 4.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.